Pasithea Therapeutics Corp (KTTA)

$0.77 +0.03 (3.48%)
Market Cap 19.20M
Revenue (ttm) 0.00
Net Income (ttm) -13.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 315,000
Avg Vol 294,856
Day's Range N/A - N/A
Shares Out 24.94M
Stochastic %K 84%
Beta 0.25
Analysts Sell
Price Target $3.00

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, inclu...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 977 3380
Address:
1111 Lincoln Road, Suite 500, Miami Beach, United States
Dickman777
Dickman777 Apr. 2 at 10:10 PM
$KTTA keep a close eye on this, just raised 60 million, MC 17 million… do the math… doesn’t belong under a dollar, and won’t be for long 😎 $AIXI $CYCN
1 · Reply
inThaJungle
inThaJungle Apr. 1 at 7:26 PM
$KTTA of course it dumps just as I buy another 500 shares
0 · Reply
inThaJungle
inThaJungle Apr. 1 at 3:58 PM
$KTTA wow.. .98 to .60.. massive volume.. wtaf? Congrats to those who BTD. 🤦🏻‍♂️ Deciding if I should load up more or not…
1 · Reply
Zskylar
Zskylar Apr. 1 at 2:49 PM
$KTTA good news going down smh
0 · Reply
Babybillysbiblebonker
Babybillysbiblebonker Apr. 1 at 1:53 PM
$KTTA I loaded 44k..... love the overreaction. low risk.
0 · Reply
StockRedBaron
StockRedBaron Apr. 1 at 1:49 PM
$KTTA It's ridiculous, they're not going to dilute-- Per DT:Cash Position The company has 40.6 months of cash left based on quarterly cash burn of -$3.8M and estimated current cash of $51.4M.
1 · Reply
trunks___
trunks___ Apr. 1 at 1:47 PM
$KTTA April fool’s day
0 · Reply
under_scored
under_scored Apr. 1 at 1:43 PM
$KTTA this is so sad
0 · Reply
GuyFawkes_EOD
GuyFawkes_EOD Apr. 1 at 12:41 PM
$KTTA you can see where someone is trying to walk the price down…. Bids for .7001, larger ask at .7002 for example
0 · Reply
daytradeforlife
daytradeforlife Apr. 1 at 11:46 AM
$KTTA so we have good news and it tanks? What in the actual fuck?!?!
0 · Reply
Latest News on KTTA
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Apr 1, 2026, 7:01 AM EDT - 4 days ago

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 7:01 AM EST - 6 weeks ago

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Jan 13, 2026, 7:01 AM EST - 2 months ago

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Dec 2, 2025, 7:00 AM EST - 4 months ago

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Nov 28, 2025, 9:20 AM EST - 4 months ago

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Nov 24, 2025, 7:00 AM EST - 4 months ago

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Nov 21, 2025, 12:35 PM EST - 4 months ago

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Nov 20, 2025, 4:01 PM EST - 4 months ago

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Nov 4, 2025, 7:03 AM EST - 5 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Sep 16, 2025, 7:03 AM EDT - 7 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:39 AM EDT - 7 months ago

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Jul 31, 2025, 7:01 AM EDT - 8 months ago

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Jun 11, 2025, 7:02 AM EDT - 10 months ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Jun 2, 2025, 8:02 AM EDT - 10 months ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

May 20, 2025, 7:01 AM EDT - 11 months ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

May 14, 2025, 7:02 AM EDT - 11 months ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

May 7, 2025, 5:00 PM EDT - 11 months ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

May 6, 2025, 11:10 AM EDT - 11 months ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

May 6, 2025, 9:29 AM EDT - 11 months ago

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

May 6, 2025, 7:03 AM EDT - 11 months ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Apr 29, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Apr 24, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Apr 10, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Feb 5, 2025, 6:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Jan 14, 2025, 8:02 AM EST - 1 year ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 26, 2024, 6:44 PM EDT - 1 year ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Sep 26, 2024, 8:56 AM EDT - 1 year ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Sep 26, 2024, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Sep 9, 2024, 8:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Sep 3, 2024, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 9:11 AM EDT - 1 year ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

May 28, 2024, 6:59 AM EDT - 2 years ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 29, 2024, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Apr 24, 2024, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Feb 13, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 8, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Jan 2, 2024, 8:35 AM EST - 2 years ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 28, 2023, 5:00 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 19, 2023, 5:19 PM EST - 2 years ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Dec 11, 2023, 8:01 AM EST - 2 years ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Nov 29, 2023, 4:27 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Nov 29, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Nov 9, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 4:14 PM EDT - 2 years ago

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Aug 1, 2023, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Jul 20, 2023, 8:43 AM EDT - 2 years ago

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Jul 20, 2023, 8:40 AM EDT - 2 years ago

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Jun 30, 2023, 9:28 AM EDT - 3 years ago

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Jun 6, 2023, 4:30 PM EDT - 3 years ago

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Dickman777
Dickman777 Apr. 2 at 10:10 PM
$KTTA keep a close eye on this, just raised 60 million, MC 17 million… do the math… doesn’t belong under a dollar, and won’t be for long 😎 $AIXI $CYCN
1 · Reply
inThaJungle
inThaJungle Apr. 1 at 7:26 PM
$KTTA of course it dumps just as I buy another 500 shares
0 · Reply
inThaJungle
inThaJungle Apr. 1 at 3:58 PM
$KTTA wow.. .98 to .60.. massive volume.. wtaf? Congrats to those who BTD. 🤦🏻‍♂️ Deciding if I should load up more or not…
1 · Reply
Zskylar
Zskylar Apr. 1 at 2:49 PM
$KTTA good news going down smh
0 · Reply
Babybillysbiblebonker
Babybillysbiblebonker Apr. 1 at 1:53 PM
$KTTA I loaded 44k..... love the overreaction. low risk.
0 · Reply
StockRedBaron
StockRedBaron Apr. 1 at 1:49 PM
$KTTA It's ridiculous, they're not going to dilute-- Per DT:Cash Position The company has 40.6 months of cash left based on quarterly cash burn of -$3.8M and estimated current cash of $51.4M.
1 · Reply
trunks___
trunks___ Apr. 1 at 1:47 PM
$KTTA April fool’s day
0 · Reply
under_scored
under_scored Apr. 1 at 1:43 PM
$KTTA this is so sad
0 · Reply
GuyFawkes_EOD
GuyFawkes_EOD Apr. 1 at 12:41 PM
$KTTA you can see where someone is trying to walk the price down…. Bids for .7001, larger ask at .7002 for example
0 · Reply
daytradeforlife
daytradeforlife Apr. 1 at 11:46 AM
$KTTA so we have good news and it tanks? What in the actual fuck?!?!
0 · Reply
trunks___
trunks___ Apr. 1 at 11:43 AM
$KTTA Fast Track Designation a real validation of science, advanced cancer data this quarter (not priced in)
0 · Reply
Mr_Stochastic
Mr_Stochastic Apr. 1 at 11:28 AM
$KTTA 🤣🤣🤣
0 · Reply
under_scored
under_scored Apr. 1 at 11:17 AM
$KTTA LOL what is this
0 · Reply
GuyFawkes_EOD
GuyFawkes_EOD Apr. 1 at 11:12 AM
$KTTA wtaf
0 · Reply
E_Ross
E_Ross Apr. 1 at 11:12 AM
$KTTA Double digit red by EOD.
0 · Reply
Codaman80
Codaman80 Apr. 1 at 11:12 AM
$KTTA Got good news today. Which means we should go into the red by days end
1 · Reply
Prosperity_Partners
Prosperity_Partners Apr. 1 at 11:04 AM
$KTTA Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity | Float: 20.3 M | IO: 53.44% | MC: 18.5 M
0 · Reply
DekmarTrades
DekmarTrades Apr. 1 at 11:04 AM
$KTTA Announces Grant of Fast Track Designation by FDA
0 · Reply
DARKP00L
DARKP00L Apr. 1 at 11:03 AM
$KTTA 07:02 on Apr. 01 2026 Pasithea Therapeutics Says FDA Grants Fast Track Designation To PAS-004 For Treatment Of NF1-Associated PN Causing Significant Morbidity #tradeideas
0 · Reply
UtahSUV
UtahSUV Mar. 18 at 9:39 PM
$KTTA shcam.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 13 at 2:02 PM
$KTTA RSI: 53.89, MACD: -0.0050 Vol: 0.06, MA20: 0.80, MA50: 0.87 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Shroomm
Shroomm Mar. 11 at 7:04 PM
$KTTA phase 3 soon
0 · Reply